Developing tests for marketed drugs
		n Currently available drugs could be targeted to appropriate patients n Leads to: n Need for archival repositories with clinical records of all drug therapies n Need to revisit stored tissues from prior clinical trials (as in original drug trials) n Need to attach PGx testing to Phase III/IV studies